The U.S. Food and Drug Administration (FDA) has granted fast track designation with rolling review to Lumicell’s LUM Imaging System for the detection and treatment of breast cancer. Fast track is given to accelerate the development and review of investigational therapies aimed at treating serious or life-threatening conditions, and addressing an unmet medical need. With this designation, Lumicell will now have the chance to engage in early and frequent interactions with the FDA to discuss…
You must be logged in to read/download the full post.
The post FDA Grants Fast Track Status, Rolling Review to Lumicell’s LUM Imaging System appeared first on BioNewsFeeds.